Add to ORKGThe management of aggressive fibromatosis (AF) is problematic, and few options are available to patients unsuitable for surgery and resistant to external-beam radiation therapy (EBRT). We report on two patients with fast-growing recurrences of AF resistant to EBRT who obtained protracted clinical benefits with 90Y-DOTATOC. 90Y-DOTATOC should be further investigated in this setting
Treatment of somatostatin receptor-positive tumors with radiolabeled somatostatin analog is a promis...
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of differen...
Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express ce...
The management of aggressive fibromatosis (AF) is problematic, and few options are available to pati...
Radiotherapy is one of the effective treatments for aggressive fibromatosis. Between January 1991 to...
Purpose: The aim of this phase II study was to evaluate the tumour response of neuroendocrine tumour...
Peptide receptor radionuclide therapy is a new treatment modality for patients with inoperable or me...
<div><p>Purpose</p><p>Although locally invasive or recurrent fibromatosis is primarily treated with ...
PURPOSE:Although locally invasive or recurrent fibromatosis is primarily treated with surgery, radio...
Radyoterapi Agresif Fibromatozis tedavisinde etkili bir tedavi yöntemidir. Bu çalışmada, Ocak 1991- ...
Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggres...
A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthe...
Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-g...
A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of ...
BACKGROUND: To determine the activity of radiotherapy in patients with inoperable desmoid-type fibro...
Treatment of somatostatin receptor-positive tumors with radiolabeled somatostatin analog is a promis...
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of differen...
Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express ce...
The management of aggressive fibromatosis (AF) is problematic, and few options are available to pati...
Radiotherapy is one of the effective treatments for aggressive fibromatosis. Between January 1991 to...
Purpose: The aim of this phase II study was to evaluate the tumour response of neuroendocrine tumour...
Peptide receptor radionuclide therapy is a new treatment modality for patients with inoperable or me...
<div><p>Purpose</p><p>Although locally invasive or recurrent fibromatosis is primarily treated with ...
PURPOSE:Although locally invasive or recurrent fibromatosis is primarily treated with surgery, radio...
Radyoterapi Agresif Fibromatozis tedavisinde etkili bir tedavi yöntemidir. Bu çalışmada, Ocak 1991- ...
Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggres...
A newly developed somatostatin radioligand, DOTA-[D-Phe1-Tyr3]-octreotide (DOTATOC), has been synthe...
Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-g...
A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of ...
BACKGROUND: To determine the activity of radiotherapy in patients with inoperable desmoid-type fibro...
Treatment of somatostatin receptor-positive tumors with radiolabeled somatostatin analog is a promis...
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of differen...
Neuroendocrine tumours (NETs) constitute a heterogeneous group of tumours that frequently express ce...